BioWorld

Jan. 4, 2008

Rights to Schizophrenia Drug Worth up to $702M for Addex

Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today) Read More

Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal

ImmunoGen Entering TAP Cancer Deal with Centocor

Gelesis Closes $16M Series A to Fund its Obesity Program

QuatRx Meets all Endpoints in Ophena Phase III Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...